• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SD filed by Pulmonx Corporation

    5/30/25 5:23:51 PM ET
    $LUNG
    Medical/Dental Instruments
    Health Care
    Get the next $LUNG alert in real time by email
    SD 1 formsd-pulmonx2025.htm SD Document

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    FORM SD
    Specialized Disclosure Report
    Pulmonx Corporation
    (Exact Name of Registrant as Specified in its Charter)
    Delaware001-3956277-0424412
    (state or other jurisdiction of incorporation or organization)(Commission File Number)(I.R.S. Employer Identification No.)
    700 Chesapeake Drive
    Redwood City, California 94063
    (Address, including zip code, of principal executive offices)
    David A. Lehman, General Counsel
    1-650-364-0400
    (Name and telephone number, including area code of the person to contact in connection with this report)


    Check the appropriate box to indicate the rule pursuant to which this form is being filed, and provide the period to which the information in this form applies:

    ☒ Rule 13p-1 under the Securities Exchange Act (17 CFR 240.13p-1) for the reporting period from January 1, 2024 to December 31, 2024.
    ☐ Rule 13q-1 under the Securities Exchange Act (17 CFR 240.13q-1) for the fiscal year ended



    Section 1 — Conflict Minerals Disclosure

    Item 1.01 Conflict Minerals Disclosure

    This Specialized Disclosure Report on Form SD of Pulmonx Corporation (“we” or “us”) is filed pursuant to Rule 13p-1 promulgated under the Securities Exchange Act of 1934, as amended (the “Rule”), and Form SD. However, in accordance with the Updated Statement on the Effect of the Court of Appeals Decision on the Conflict Minerals Rule issued by the Division of Corporate Finance of the Securities and Exchange Commission (“SEC”) on April 7, 2017 (the “April 2017 Guidance”), we have not provided disclosure under Item 1.01(c) of Form SD.

    The Rule was adopted by the SEC under Section 1502 of the Dodd-Frank Wall Street Reform and Consumer Protection Act to implement reporting and disclosure requirements related to “conflict minerals,” defined by the SEC as tantalum, tin, tungsten and gold (collectively, “3TG”). Pursuant to the Rule, a publicly traded company must submit a Specialized Disclosure Report to the SEC if it manufactures or contracts to manufacture products during the relevant reporting period that contain 3TG that are necessary to the functionality or production of the product. In that event, the company must conduct a good faith, reasonable country-of-origin inquiry (“RCOI”) to determine whether the 3TG originated in the Democratic Republic of Congo or adjoining countries (Angola, Burundi, The Central African Republic, The Republic of the Congo, Rwanda, South Sudan, Tanzania, Uganda and Zambia) (together, the “Covered Countries”). If the company has reason to believe that any 3TG in its products may have originated in the Covered Countries, or if it is unable to determine the country of origin of the 3TG in its products, or that the 3TG in its products came entirely from recycled and scrap sources, then the company must conduct due diligence on the source and chain of custody of the 3TG.

    Item 1.01 Conflict Minerals Disclosure and Report

    Pulmonx Corporation is a medical device company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (“COPD”).

    Our portfolio of products includes the (i) Zephyr® Endobronchial Valve (“Zephyr Valve”), which is an implantable device used to occlude all airways feeding the hyperinflated lobe of a lung that is most diseased with emphysema/COPD; (ii) Zephyr Endobronchial Delivery Catheter (“Zephyr Catheter”), which is used to implant the Zephyr Valve into the hyperinflated lung; and (iii) the Chartis® Pulmonary Assessment System, which is comprised of a proprietary balloon catheter (“Chartis Catheter”) and the Chartis Pulmonary Assessment System Console (“Chartis Console” and together with the Zephyr Valve, Zephyr Catheter and Chartis Catheter, hereinafter defined as the “Products”) with flow and pressure sensors used to assess the presence of collateral ventilation in the lung.

    With respect to these Products that we either manufactured or contracted to have manufactured in the reporting period from January 1, 2024 to December 31, 2024 (the “Reporting Period”), we have determined the presence of tin and gold in printed circuit board assemblies and wire harness assemblies contained in our Chartis Console. None of our other Products contain 3TG. As a result, only Chartis Consoles, the manufacture of which was completed during the Reporting Period, are considered in-scope for purposes of this Form SD.

    The Chartis Console is assembled at our manufacturing facility in Redwood City, California. We do not purchase 3TG from mines, smelters or refiners, and there are many third parties in the supply chain between the ultimate manufacture of the Chartis Console and the original sources of 3TG. Tracing these minerals to their sources is a challenge that requires us to rely on the suppliers that provide us with materials and components containing these minerals. We rely on these suppliers to assist us in our efforts to conduct our RCOI and achieve supply chain transparency, including obtaining information regarding the countries of origin of the 3TG. The information provided by suppliers may be inaccurate or incomplete or subject to other irregularities. In addition, because of our location within the supply chain in relation to the actual extraction and transport of 3TG, our ability to verify the accuracy of information reported by suppliers is limited.

    Reasonable Country of Origin Inquiry

    In accordance with the Rule, we conducted a good faith RCOI with our suppliers for the Reporting Period to determine whether any of the 3TG that were necessary to the functionality or production of the Chartis Console originated in the Covered Countries and whether any of the 3TG may be from recycled or scrap sources. We identified those suppliers that provided components or materials for the manufacture, during the Reporting Period, of the Chartis Console that contained 3TG necessary to the functionality or production of the Chartis Console (“Identified Suppliers”). The following steps were then performed as part of our RCOI:

    •To the extent available, we obtained a copy of each Identified Supplier’s conflict minerals statement and/or policy, or any other declarations relating to their sourcing of 3TG;
    •We requested a completed Conflict Minerals Reporting Template (“CMRT”), a standardized reporting template designed to facilitate the transfer of information through the supply chain regarding mineral country of origin and the smelters and refiners being utilized developed by the Responsible Minerals Initiative, from each Identified Supplier. The CMRT asks for disclosure of specified information regarding the inclusion of 3TG in the products supplied to us, the smelter or refiner used, and the country of origin of the 3TG;
    •We assessed the CMRTs received and, where appropriate, contacted the supplier for clarification or further information; and
    •Where further inquiry was needed, we reviewed information available from other public sources regarding the use and country of origin of 3TG in a supplier’s products.




    Determination

    We received responses from one hundred percent (100%) of our Identified Suppliers, which encompassed a total of thirteen (13) suppliers; however, we are unable to determine with absolute assurance the countries of origin of the 3TG in the Chartis Console, and, therefore, cannot exclude the possibility that some may have originated in the Covered Countries. Because of our size and the fact that we buy primarily from smaller suppliers that lack supply chain infrastructure, it is difficult to identify sources upstream from our direct suppliers. We expect to continue to engage with our suppliers to obtain current, accurate and complete information related to their supply chain.

    Pursuant to the April 2017 Guidance, we have elected not to file a disclosure under Item 1.01(c) of Form SD and we are providing only the disclosure required under the provisions of paragraphs (a) and (b) of Item 1.01 of Form SD.

    Additional Information

    This Form SD is publicly posted on our webpage at http://investors.pulmonx.com as well as the SEC’s EDGAR database at www.sec.gov. The content of any referenced website in this Form SD is included for general information only and is not incorporated by reference into and should not be considered part of this Form SD.

    Section 2 - Resource Extraction Issuer Disclosure

    Item 2.01 Resource Extraction Issuer Disclosure and Report

    Not applicable

    Section 3 - Exhibits

    Item 3.01 Exhibits

    Not applicable.



    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the duly authorized undersigned.

    Pulmonx Corporation
     By: /s/ David A. LehmanDate: May 30, 2025
    David A. Lehman
    General Counsel


    Get the next $LUNG alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $LUNG

    DatePrice TargetRatingAnalyst
    3/10/2025$17.00Buy
    D. Boral Capital
    12/11/2024$17.00 → $7.50Buy → Neutral
    Citigroup
    6/4/2024$12.00Buy
    Lake Street
    2/23/2024$16.00 → $14.00Overweight → Equal Weight
    Wells Fargo
    9/5/2023$18.00Buy
    Craig Hallum
    2/27/2023$10.00 → $15.00Equal Weight → Overweight
    Wells Fargo
    1/3/2023$8.00Neutral → Underperform
    BofA Securities
    12/12/2022$14.00 → $10.00Neutral → Buy
    Citigroup
    More analyst ratings

    $LUNG
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • PRESIDENT AND CEO Williamson Steven S. bought $97,436 worth of shares (14,245 units at $6.84), increasing direct ownership by 7% to 219,531 units (SEC Form 4)

      4 - Pulmonx Corp (0001127537) (Issuer)

      8/22/24 6:41:17 PM ET
      $LUNG
      Medical/Dental Instruments
      Health Care

    $LUNG
    Financials

    Live finance-specific insights

    See more
    • Pulmonx Reports First Quarter 2025 Financial Results

      REDWOOD CITY, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Pulmonx Corporation (NASDAQ:LUNG) ("Pulmonx" or the "Company"), a global leader in minimally invasive treatments for lung disease, today reported financial results for the first quarter of 2025 ended March 31, 2025. Recent Highlights Achieved worldwide revenue of $22.5 million in the first quarter of 2025, a 20% increase over the same period last year and an increase of 21% on a constant currency basisDelivered $8.3 million in international revenue in the first quarter of 2025, representing 39% year-over-year growth and an increase of 43% on a constant currency basisDelivered $14.2 million in U.S. revenue in the first quarter of 20

      4/30/25 4:05:00 PM ET
      $LUNG
      Medical/Dental Instruments
      Health Care
    • Pulmonx to Report First Quarter 2025 Financial Results on April 30, 2025

      REDWOOD CITY, Calif., April 16, 2025 (GLOBE NEWSWIRE) -- Pulmonx Corporation (NASDAQ:LUNG) ("Pulmonx"), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the first quarter of 2025 after the close of trading on Wednesday, April 30, 2025. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET. A live and archived webcast of the event will be available on the "Investors" section of the Pulmonx website at https://investors.pulmonx.com/. About Pulmonx CorporationPulmonx Corporation (NASDAQ:LUNG) is a global leader in minimally invasive treatments for chroni

      4/16/25 4:05:00 PM ET
      $LUNG
      Medical/Dental Instruments
      Health Care
    • Pulmonx Reports Record Fourth Quarter and Full Year 2024 Financial Results

      REDWOOD CITY, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Pulmonx Corporation (NASDAQ:LUNG) ("Pulmonx" or the "Company"), a global leader in minimally invasive treatments for lung disease, today reported financial results for the fourth quarter and full year ended December 31, 2024. Recent Highlights Delivered $83.8 million in worldwide revenue for the full year of 2024, a 22% increase over the prior yearAchieved record worldwide revenue of $23.8 million for the fourth quarter of 2024, a 23% increase over the same period last year on an as reported and constant currency basisSet a record of $15.9 million and $56.5 million in U.S. revenue for the fourth quarter 2024 and the full year 20

      2/19/25 4:05:00 PM ET
      $LUNG
      Medical/Dental Instruments
      Health Care

    $LUNG
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • D. Boral Capital initiated coverage on Pulmonx with a new price target

      D. Boral Capital initiated coverage of Pulmonx with a rating of Buy and set a new price target of $17.00

      3/10/25 8:07:21 AM ET
      $LUNG
      Medical/Dental Instruments
      Health Care
    • Pulmonx downgraded by Citigroup with a new price target

      Citigroup downgraded Pulmonx from Buy to Neutral and set a new price target of $7.50 from $17.00 previously

      12/11/24 7:54:19 AM ET
      $LUNG
      Medical/Dental Instruments
      Health Care
    • Lake Street initiated coverage on Pulmonx with a new price target

      Lake Street initiated coverage of Pulmonx with a rating of Buy and set a new price target of $12.00

      6/4/24 8:21:23 AM ET
      $LUNG
      Medical/Dental Instruments
      Health Care

    $LUNG
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Pulmonx to Present at the Goldman Sachs 46th Annual Global Healthcare Conference

      REDWOOD CITY, Calif., May 28, 2025 (GLOBE NEWSWIRE) -- Pulmonx Corporation (NASDAQ:LUNG) ("Pulmonx" or the "Company"), a global leader in minimally invasive treatments for lung disease, today announced the company will be presenting at the Goldman Sachs 46th Annual Global Health Care Conference in Miami on Wednesday, June 11, 2025, at 7:00 AM PT / 10:00 AM ET. A live and archived webcast of the presentation will be available on "Investors" section of the Pulmonx website at https://investors.pulmonx.com/. About Pulmonx Corporation Pulmonx Corporation (NASDAQ:LUNG) is a global leader in minimally invasive treatments for chronic obstructive pulmonary disease (COPD). Pulmonx's Zephyr®

      5/28/25 4:05:00 PM ET
      $LUNG
      Medical/Dental Instruments
      Health Care
    • Pulmonx to Present at the Bank of America Securities 2025 Health Care Conference

      REDWOOD CITY, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Pulmonx Corporation (NASDAQ:LUNG) ("Pulmonx") a global leader in minimally invasive treatments for severe lung disease, today announced the company will be presenting at the Bank of America Securities 2025 Health Care Conference in Las Vegas on Wednesday, May 14, 2025, at 9:35 AM PT / 12:35 PM ET. A live and archived webcast of the presentation will be available on "Investors" section of the Pulmonx website at https://investors.pulmonx.com/. About Pulmonx CorporationPulmonx Corporation (NASDAQ:LUNG) is a global leader in minimally invasive treatments for chronic obstructive pulmonary disease (COPD). Pulmonx's Zephyr® Endobronchial Va

      5/1/25 4:05:00 PM ET
      $LUNG
      Medical/Dental Instruments
      Health Care
    • Pulmonx Reports First Quarter 2025 Financial Results

      REDWOOD CITY, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Pulmonx Corporation (NASDAQ:LUNG) ("Pulmonx" or the "Company"), a global leader in minimally invasive treatments for lung disease, today reported financial results for the first quarter of 2025 ended March 31, 2025. Recent Highlights Achieved worldwide revenue of $22.5 million in the first quarter of 2025, a 20% increase over the same period last year and an increase of 21% on a constant currency basisDelivered $8.3 million in international revenue in the first quarter of 2025, representing 39% year-over-year growth and an increase of 43% on a constant currency basisDelivered $14.2 million in U.S. revenue in the first quarter of 20

      4/30/25 4:05:00 PM ET
      $LUNG
      Medical/Dental Instruments
      Health Care

    $LUNG
    Leadership Updates

    Live Leadership Updates

    See more

    $LUNG
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $LUNG
    SEC Filings

    See more
    • Pulmonx Announces Appointment of Mehul Joshi as Chief Financial Officer

      REDWOOD CITY, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (NASDAQ:LUNG) ("Pulmonx" or the "Company"), a global leader in minimally invasive treatments for lung disease, today announced the appointment of Mehul Joshi as Chief Financial Officer, effective April 3, 2024. He succeeds John McKune, who has served as the Company's Interim Chief Financial Officer since October 10, 2023, and will transition to his prior role as Vice President, Corporate Controller. "Mehul is an exceptionally accomplished financial executive and I am excited to welcome him to our leadership team. His proven track record of leading global finance teams within large, diversified companies makes him

      4/2/24 4:05:00 PM ET
      $LUNG
      Medical/Dental Instruments
      Health Care
    • Pulmonx Announces Retirement of CEO Glen French and Appointment of Industry Veteran Steve Williamson as President and Chief Executive Officer

      REDWOOD CITY, Calif., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (NASDAQ:LUNG) ("Pulmonx" or the "Company"), a global leader in minimally invasive treatments for lung disease, today announced that Glen French will retire as the Company's President and Chief Executive Officer, effective March 15, 2024, following over nine years of service to Pulmonx. Concurrently, the Company announced the appointment of Steve Williamson as President and Chief Executive Officer, and as a member of the Company's Board of Directors, also effective March 15, 2024. Mr. French will serve as a Senior Advisor to Mr. Williamson until May 1, 2024 to ensure a seamless transition and then remain a member of

      2/21/24 4:05:00 PM ET
      $LUNG
      Medical/Dental Instruments
      Health Care
    • The Honest Company Announces Appointment of Michael Barkley, Alissa Hsu Lynch, and Andrea Turner to the Board of Directors

      LOS ANGELES, Dec. 11, 2023 (GLOBE NEWSWIRE) -- The Honest Company (NASDAQ:HNST), a digitally-native consumer products company dedicated to creating clean- and sustainably-designed products spanning baby care, beauty, personal care, wellness and household care, today announced that Michael Barkley, Former Chief Executive Officer of Kind LLC, Alissa Hsu Lynch, Former Global Head of MedTech Strategy and Solutions for Google Cloud, and Andrea Turner, Former Senior Vice President, Global Customer Service & Logistics at Mondelēz International, Inc., have been appointed to its Board of Directors effective December 8, 2023. "We are pleased to welcome Michael, Alissa and Andrea to our board of dir

      12/11/23 9:00:00 AM ET
      $HNST
      $LUNG
      Catalog/Specialty Distribution
      Consumer Discretionary
      Medical/Dental Instruments
      Health Care
    • Director French Glendon E. Iii sold $157,000 worth of shares (20,000 units at $7.85), decreasing direct ownership by 2% to 991,974 units (SEC Form 4)

      4 - Pulmonx Corp (0001127537) (Issuer)

      3/21/25 6:14:28 PM ET
      $LUNG
      Medical/Dental Instruments
      Health Care
    • Chief Financial Officer & PAO Joshi Mehul sold $102,414 worth of shares (14,384 units at $7.12) and was granted 108,000 shares, increasing direct ownership by 73% to 221,986 units (SEC Form 4)

      4 - Pulmonx Corp (0001127537) (Issuer)

      3/5/25 6:12:01 PM ET
      $LUNG
      Medical/Dental Instruments
      Health Care
    • PRESIDENT AND CEO Williamson Steven S. sold $197,699 worth of shares (27,689 units at $7.14) and was granted 181,696 shares, increasing direct ownership by 69% to 376,038 units (SEC Form 4)

      4 - Pulmonx Corp (0001127537) (Issuer)

      3/5/25 6:09:24 PM ET
      $LUNG
      Medical/Dental Instruments
      Health Care
    • SEC Form SD filed by Pulmonx Corporation

      SD - Pulmonx Corp (0001127537) (Filer)

      5/30/25 5:23:51 PM ET
      $LUNG
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Pulmonx Corporation

      SCHEDULE 13G/A - Pulmonx Corp (0001127537) (Subject)

      5/13/25 4:23:45 PM ET
      $LUNG
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Pulmonx Corporation

      SCHEDULE 13G/A - Pulmonx Corp (0001127537) (Subject)

      5/12/25 10:39:51 AM ET
      $LUNG
      Medical/Dental Instruments
      Health Care

    $LUNG
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Pulmonx Corporation

      SC 13G/A - Pulmonx Corp (0001127537) (Subject)

      11/14/24 7:47:49 PM ET
      $LUNG
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Pulmonx Corporation

      SC 13G/A - Pulmonx Corp (0001127537) (Subject)

      11/12/24 10:34:16 AM ET
      $LUNG
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Pulmonx Corporation

      SC 13G/A - Pulmonx Corp (0001127537) (Subject)

      11/8/24 10:35:45 AM ET
      $LUNG
      Medical/Dental Instruments
      Health Care